CNSY logo

CNSY Cerenome, Inc.

NASDAQ · Medical - Pharmaceuticals · Healthcare

$0.63
-0.07 (-10.29%)

Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Market Cap: $6.16Mcerenome.com

Price

No data yet.

Social Signal Score

48
5d
—
30d
48
7 mentions
—
60d
49
10 mentions
—
90d
48
13 mentions
—
news: 13

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0

Revenue

$722.0K-76.15%
$0.00$1.59M$3.18M$4.77M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-6.05
$-9.06–$-4.71
1 analysts
FY2026
$-4.51
$-4.62–$-4.40
1 analysts
FY2027
$-3.49
$-4.35–$-2.61
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marc H. Hedrick
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
28
Beta
1.49
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-69.02
cerenome.com